Drugs / LTX-002
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07660614 | Apr 2026 → Jun 2031 expected | amyotrophic lateral sclerosis | Leal Therapeutics, Inc | Recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-06-22 | Leal Therapeutics, Inc | Leal Therapeutics Doses First Patient in NeurALS Phase 1/2 Trial of LTX-002 for Amyotrophic Lateral Sclerosis (ALS) lealtx.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LTX-002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07660614 ↗ |
| Modality | Antisense oligonucleotide | “LTX-002 is an antisense oligonucleotide (ASO)” NCT07660614 ↗ |
| Route | Intrathecal | “Intrathecally Administered” NCT07660614 ↗ |
| Target | SPTLC1 | “targeting SPTLC1 messenger RNA (mRNA)” NCT07660614 ↗ |